Literature DB >> 26175151

Lysophosphatidic Acid Initiates Epithelial to Mesenchymal Transition and Induces β-Catenin-mediated Transcription in Epithelial Ovarian Carcinoma.

Rebecca J Burkhalter1, Suzanne D Westfall2, Yueying Liu3, M Sharon Stack4.   

Abstract

During tumor progression, epithelial ovarian cancer (EOC) cells undergo epithelial-to-mesenchymal transition (EMT), which influences metastatic success. Mutation-dependent activation of Wnt/β-catenin signaling has been implicated in gain of mesenchymal phenotype and loss of differentiation in several solid tumors; however, similar mutations are rare in most EOC histotypes. Nevertheless, evidence for activated Wnt/β-catenin signaling in EOC has been reported, and immunohistochemical analysis of human EOC tumors demonstrates nuclear staining in all histotypes. This study addresses the hypothesis that the bioactive lipid lysophosphatidic acid (LPA), prevalent in the EOC microenvironment, functions to regulate EMT in EOC. Our results demonstrate that LPA induces loss of junctional β-catenin, stimulates clustering of β1 integrins, and enhances the conformationally active population of surface β1 integrins. Furthermore, LPA treatment initiates nuclear translocation of β-catenin and transcriptional activation of Wnt/β-catenin target genes resulting in gain of mesenchymal marker expression. Together these data suggest that LPA initiates EMT in ovarian tumors through β1-integrin-dependent activation of Wnt/β-catenin signaling, providing a novel mechanism for mutation-independent activation of this pathway in EOC progression.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  LPA; Wnt signaling; integrin; lysophospholipid; ovarian cancer; β-catenin (β-catenin)

Mesh:

Substances:

Year:  2015        PMID: 26175151      PMCID: PMC4571965          DOI: 10.1074/jbc.M115.641092

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

1.  Integrin regulation of beta-catenin signaling in ovarian carcinoma.

Authors:  Rebecca J Burkhalter; Jaime Symowicz; Laurie G Hudson; Cara J Gottardi; M Sharon Stack
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

2.  Dispersal of epithelial cancer cell colonies by lysophosphatidic acid (LPA).

Authors:  Jérôme Jourquin; Neng Yang; Yoonseok Kam; Cherise Guess; Vito Quaranta
Journal:  J Cell Physiol       Date:  2006-02       Impact factor: 6.384

Review 3.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

4.  Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention.

Authors:  Eva Krieghoff; Jürgen Behrens; Bernhard Mayr
Journal:  J Cell Sci       Date:  2006-04-01       Impact factor: 5.285

Review 5.  Towards an integrated view of Wnt signaling in development.

Authors:  Renée van Amerongen; Roel Nusse
Journal:  Development       Date:  2009-10       Impact factor: 6.868

6.  G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway.

Authors:  Ming Yang; Wendy W Zhong; Neelam Srivastava; Anthony Slavin; Jianxin Yang; Timothy Hoey; Songzhu An
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

7.  The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer.

Authors:  C E Ford; G Punnia-Moorthy; C E Henry; E Llamosas; S Nixdorf; J Olivier; R Caduff; R L Ward; V Heinzelmann-Schwarz
Journal:  Gynecol Oncol       Date:  2014-06-10       Impact factor: 5.482

Review 8.  Wnt/beta-catenin signaling pathway as a novel cancer drug target.

Authors:  Hue H Luu; Ruiwen Zhang; Rex C Haydon; Elizabeth Rayburn; Quan Kang; Weike Si; Jong Kyung Park; Hui Wang; Ying Peng; Wei Jiang; Tong-Chuan He
Journal:  Curr Cancer Drug Targets       Date:  2004-12       Impact factor: 3.428

9.  Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.

Authors:  Rebecca C Arend; Angelina I Londoño-Joshi; Rajeev S Samant; Yonghe Li; Michael Conner; Bertha Hidalgo; Ronald D Alvarez; Charles N Landen; J Michael Straughn; Donald J Buchsbaum
Journal:  Gynecol Oncol       Date:  2014-04-13       Impact factor: 5.482

10.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Authors:  Rong Wu; Neali Hendrix-Lucas; Rork Kuick; Yali Zhai; Donald R Schwartz; Aytekin Akyol; Samir Hanash; David E Misek; Hidetaka Katabuchi; Bart O Williams; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

View more
  30 in total

1.  High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro.

Authors:  Fan Wang; Jeremy T-H Chang; Chester Jingshiu Kao; R Stephanie Huang
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

2.  Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via Gαi2, Src, and HIF1α signaling nexus.

Authors:  Ji Hee Ha; Jeremy D Ward; Rangasudhagar Radhakrishnan; Muralidharan Jayaraman; Yong Sang Song; Danny N Dhanasekaran
Journal:  Oncotarget       Date:  2016-06-21

Review 3.  Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting.

Authors:  Annalisa Contursi; Angela Sacco; Rosalia Grande; Melania Dovizio; Paola Patrignani
Journal:  Cell Mol Life Sci       Date:  2017-05-09       Impact factor: 9.261

4.  Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis.

Authors:  Pengxiu Cao; Yoshiro Aoki; Linda Badri; Natalie M Walker; Casey M Manning; Amir Lagstein; Eric R Fearon; Vibha N Lama
Journal:  J Clin Invest       Date:  2017-02-27       Impact factor: 14.808

5.  Lysophosphatidylcholine acyltransferase 3 deficiency impairs 3T3L1 cell adipogenesis through activating Wnt/β-catenin pathway.

Authors:  Chunyan Feng; Bin Lou; Jibin Dong; Zhiqiang Li; Yunqin Chen; Yue Li; Xuemei Zhang; Xian-Cheng Jiang; Tingbo Ding
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-04-17       Impact factor: 4.698

Review 6.  Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.

Authors:  Gabor J Tigyi; Junming Yue; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Louisa Balazs; Guannan Zhao; Sue Chin Lee
Journal:  Adv Biol Regul       Date:  2018-09-16

7.  Discoidin Domain Receptor 2 Mediates Lysophosphatidic Acid-Induced Ovarian Cancer Aggressiveness.

Authors:  Bo Young Jeong; Kyung Hwa Cho; Se-Hee Yoon; Chang Gyo Park; Hwan-Woo Park; Hoi Young Lee
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 8.  G Protein-Coupled Receptors in Cancer.

Authors:  Rachel Bar-Shavit; Myriam Maoz; Arun Kancharla; Jeetendra Kumar Nag; Daniel Agranovich; Sorina Grisaru-Granovsky; Beatrice Uziely
Journal:  Int J Mol Sci       Date:  2016-08-12       Impact factor: 5.923

Review 9.  Wnt5a Signaling in Cancer.

Authors:  Marwa S Asem; Steven Buechler; Rebecca Burkhalter Wates; Daniel L Miller; M Sharon Stack
Journal:  Cancers (Basel)       Date:  2016-08-26       Impact factor: 6.639

10.  EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling.

Authors:  Meng Xu; Zhikui Liu; Cong Wang; Bowen Yao; Xin Zheng
Journal:  Oncotarget       Date:  2017-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.